Neurocrine Biosciences | NBIX - Уставный капитал обыкновенных акций





Уставный капитал обыкновенных акций Изменить Дата
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
ALKERMES USD 165.61M 503K 2025-12
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amgen USD 540M 1000K 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Cytokinetics USD 122.26M 145K 2025-12
Enanta Pharmaceuticals USD 212K 1000 2023-12
Exelixis USD 262.48M 5.61M 2025-12
Gilead Sciences USD 1.24B 1000K 2025-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Pfizer USD 5.7B 13M 2026-03
Prothena USD 53.83M 3K 2025-12
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Repligen USD 56.4M 74K 2026-03
Rigel Pharmaceuticals USD 17K 158K 2024-06
Sarepta Therapeutics USD 104.96M 196K 2025-12
Teva Pharmaceutical Industries USD 1.16B 16.72M 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03
Xoma USD 87K 1000 2024-06